Kala Pharmaceuticals, Inc. (0JQ2.L)
| Chiusura precedente | 1,9350 |
| Aperto | 1,8520 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 1,8520 - 2,0350 |
| Intervallo di 52 settimane | 1,8520 - 2,0350 |
| Volume | 5.762 |
| Media Volume | N/D |
| Capitalizzazione | 47,468M |
| Beta (5 anni mensile) | 0,50 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,1060 |
| Prossima data utili | 03 nov 2021 - 08 nov 2021 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 70,000 shares of Kala Pharmaceuticals common stock to ten new employees. The stock options were granted on October 18, 2021. The gr
- GlobeNewswire
Kala Pharmaceuticals Announces Appointment of C. Daniel Myers to Board of Directors
WATERTOWN, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the appointment of C. Daniel Myers to its Board of Directors. Mr. Myers, who has more than 35 years of ophthalmic pharmaceutical experience, will serve as a Class III director, and join both the Compensation and Nominating and Corporate
- GlobeNewswire
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021
WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in September 2021: H.C. Wainwright 23rd Annual Global Investment ConferenceA pre-recorded presentation will be made available beginning Monday, S
